HilleVax (NASDAQ:HLVX – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares HilleVax and ProKidney’s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
HilleVax | N/A | N/A | -$123.57 million | ($3.30) | -4.37 |
ProKidney | N/A | N/A | -$35.47 million | ($0.57) | -4.39 |
ProKidney is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
Profitability
This table compares HilleVax and ProKidney’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
HilleVax | N/A | -56.18% | -43.75% |
ProKidney | N/A | N/A | -8.09% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for HilleVax and ProKidney, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
HilleVax | 0 | 0 | 4 | 0 | 3.00 |
ProKidney | 0 | 2 | 2 | 0 | 2.50 |
HilleVax currently has a consensus price target of $29.00, indicating a potential upside of 101.11%. ProKidney has a consensus price target of $7.25, indicating a potential upside of 190.00%. Given ProKidney’s higher probable upside, analysts plainly believe ProKidney is more favorable than HilleVax.
Volatility & Risk
HilleVax has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
Summary
ProKidney beats HilleVax on 6 of the 11 factors compared between the two stocks.
About HilleVax
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.